CML HealthCare Inc. Announces Exclusive Licensing Agreement

CML HealthCare Inc. Announces Exclusive Licensing Agreement With
Mitomics Inc. for a New Specialty Prostate Cancer Test 
MISSISSAUGA, ONTARIO -- (Marketwire) -- 11/20/12 -- CML HealthCare
Inc. (TSX:CLC) (the "Company" or "CML"), a leading provider of
medical diagnostic services in Canada, today announced an exclusive
licensing agreement with Mitomics Inc., the world's premier developer
of mitochondrial DNA-based tests for early disease detection, to make
available the Prostate Core Mitomic Test(TM) (PCMT) to Canadians.  
Today approximately 70% of first prostate biopsies come back
negative, but half of those patients over time will be diagnosed with
prostate cancer and many will require additional biopsies as part of
the diagnosis. Mitomics' PCMT can detect the presence of malignant
cells by applying the science of mitochondrial DNA analysis to tissue
samples from the first prostate biopsy. Results from PCMT can assist
in the diagnosis and management of prostate cancer and may eliminate
the need for a subsequent biopsy. Under the agreement, Canadian
urologists will be able to order PCMT through CML HealthCare in early
2013. Specimens will be analyzed at Mitomics' CLIA laboratory in
Aurora, Colorado.  
"CML HealthCare is proud to offer this advanced diagnostic to assist
urologists across Canada with their diagnosis and management of
prostate cancer," said Thomas Wellner, President and Chief Executive
Officer of CML HealthCare. "The Mitomics relationship is another
example of our commitment to add innovative, non-government pay
medical diagnostics to our test menu while leveraging our existing
business platform. We believe PCMT will provide significant benefits
to patients, physicians and the health care system," continued Mr.
Wellner. 
"With their extensive laboratory and distribution network, CML
HealthCare is the ideal partner to offer our Prostate Core Mitomic
Test to urologists across Canada," added Robert Poulter, President
and Chief Executive Officer of Mitomics. "This agreement is aligned
with our commercial strategy to provide broad access to PCMT and
further validates the strong demand from physicians to improve the
diagnosis of prostate cancer for patients." 
According to the Canadian Cancer Society, prostate cancer is the most
common cancer among Canadian 
men (excluding non-melanoma skin
cancer). One in seven men will develop prostate cancer during his
lifetime and one in 28 will die of it. In 2012, an estimated 26,500
men will be diagnosed with prostate cancer and 4,000 will die of it. 
About the Prostate Core Mitomic Test(TM) (PCMT) 
PCMT is a highly advanced, patented test based on the science of
mitochondrial DNA (mtDNA). Using previously obtained prostate biopsy
tissue, PCMT can determine the presence of malignant cells via a
cancerization field effect by detecting underlying molecular
alterations in normal-appearing tissue. This is all performed quickly
and easily with a simple lab test.  
Conducted in Mitomics' CLIA-certified lab, PCMT uses existing
prostate-biopsy material to detect mitochondrial-DNA alterations
(called "deletions") that appear in benign tissue when a tumour is
present in adjacent tissue. These molecular alterations, known as the
cancerization field effect, enhance tumor detection in instances
where biopsy cores appear histologically benign because they have
failed to intersect tumor tissue. Initial prostate biopsies can miss
one-third of all cancers, leading to false-negative results. PCMT
provides the clinician with insights far surpassing conventional
screening methods. The concurrent high sensitivity of 85% and
negative predictive value of 92% contribute unprecedented strength to
this assay through its ability to identify prostate cancer. For more
information or to order PCMT, please visit
http://www.mitomicsinc.com/prostate-core-mitomic-test/. For more
information please visit www.mitomicsinc.com. Timing of PCMT
availability in Canada from CML HealthCare is scheduled for the first
quarter of 2013.  
About Mitomics 
Mitomics provides clinical solutions that deliver the earliest
possible detection of disease through mitochondrial DNA-based
testing. Using proprietary technology, called Mitomic Technology(TM),
the company has developed a platform on which it is developing an
array of molecular tests that address significant needs in oncology.
The company's flagship product, the Prostate Core Mitomic Test(TM)
(PCMT(TM)), was launched in 2011, and is the most accurate and safest
test currently on the market for prostate cancer screening. PCMT is a
simple test, conducted in Mitomics' CLIA-certified lab, using
existing biopsy tissue to identify the biomarker associated with
malignant cells in benign tissue. Mitomics is currently using its
platform of mtDNA testing to develop similar tests for the detection
of breast cancer, bladder cancer, thyroid cancer, melanoma, ovarian
cancer, pancreatic cancer, uterine cancer, and endometriosis.
Mitomics is headquartered in Thunder Bay, Ontario, Canada.
www.mitomicsinc.com. 
About CML HealthCare Inc. 
Based in Mississauga, Ontario, CML HealthCare Inc. is Canada's
leading community-based, medical diagnostic services provider
operating 140 laboratory collection centres in Ontario, 94 imaging
centres in Ontario and British Columbia, and a reference laboratory
in Ontario focused on specialized coagulation testing for customers
worldwide. CML is publicly-traded on the Toronto Stock Exchange under
the symbol "CLC" and has approximately 89.8 million common shares
outstanding. For more information, please visit www.cmlhealthcare.com
and follow us on Twitter @cmlhealthcare.  
Caution concerning forward-looking statements 
This document includes forward-looking statements within the meaning
of certain securities laws, including the "safe harbour" provisions
of the Securities Act (Ontario) and other provincial or territorial
securities law in Canada. These forward-looking statements include,
among others, statements with respect to our objectives, goals and
strategies to achieve those objectives and goals, as well as
statements with respect to our beliefs, plans, objectives,
expectations, anticipations, estimates and intentions. The words
"may", "will", "could", "should", "would", "suspect", "outlook",
"believe", "plan", "anticipate", "estimate", "expect", "intend",
"forecast", "objective" and "continue" (or the negative thereof), and
words and expressions of similar import, are intended to identify
forward-looking statements. 
By their very nature, forward-looking statements involve inherent
risks and uncertainties, both general and specific, which give rise
to the possibility that predictions, forecasts, projections and other
forward-looking statements will not be achieved. Certain material
factors or assumptions are applied in making forward-looking
statements and actual results may differ materially from those
expressed or implied in such statements. We caution readers not to
place undue reliance on these statements, as a number of important
factors, many of which are beyond our control, could cause our actual
results to differ materially from the beliefs, plans, objectives,
expectations, anticipations, estimates and intentions expressed in
such forward-looking statements. These factors include, but are not
limited to: dependence on government-based revenues in Canada;
general economic conditions; pending and proposed legislative or
regulatory developments in Canada including the impact of changes in
laws, regulations and the enforcement thereof; reliance on funding
models
 in Canada; operational and infrastructure risks including
possible equipment failure and performance of information technology
systems; intensifying competition resulting from established
competitors and new entrants in the businesses in which we operate;
our ability to complete strategic acquisitions and to integrate our
acquisitions successfully; insurance coverage of sufficient scope to
satisfy any liability claims; fluctuations in total patient
referrals; technological change and obsolescence; loss of services of
key senior management personnel; privacy laws; ability to pay
dividends in the future; structural subordination of common shares;
leverage and restrictive covenants; fluctuations in cash timing and
amount of capital expenditures; tax-related risks; unpredictability
and volatility of the price of common shares; dilution; and future
sales of common shares.  
We caution that the foregoing list of important factors that may
affect future results is not exhaustive. When reviewing our
forward-looking statements, investors and others should carefully
consider the foregoing factors and other uncertainties and potential
events. Additional information about factors that may cause actual
results to differ materially from expectations, and about material
factors or assumptions applied in making forward-looking statements,
may be found in the "Risk Factors" section of our Annual Information
Form, under "Business Risks" and elsewhere in our Management's
Discussion and Analysis of Operating Results and Financial Position
("MD&A") for the year ended December 31, 2011 and elsewhere in our
filings with Canadian securities regulators. Except as required by
Canadian securities law, we do not undertake to update any
forward-looking statements, whether written or oral, that may be made
from time to time by us or on our behalf. Such statements speak only
as of the date made. 
Contacts:
CML HealthCare Inc.
Alice Dunning, MBA, CFA
Director, Corporate Communications
(905) 565-0043 ext. 3472
(905) 565-2844 (FAX)
dunninga@cml.ca
www.cmlhealthcare.com
Contacts:
Mitomics Inc.
TMX Equicom
Shaun Smith
Manager, Media Relations
416-815-0700 ext. 252
ssmith@tmxequicom.com